Market closed
Dyne Therapeutics/$DYN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Ticker
$DYN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
191
Website
DYN Metrics
BasicAdvanced
$924M
-
-$3.37
1.11
-
Price and volume
Market cap
$924M
Beta
1.11
52-week high
$47.45
52-week low
$6.36
Average daily volume
2.3M
Financial strength
Current ratio
15.601
Quick ratio
15.199
Long term debt to equity
3.039
Total debt to equity
3.809
Management effectiveness
Return on assets (TTM)
-50.20%
Return on equity (TTM)
-88.03%
Valuation
Price to book
1.33
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-2.61
Growth
Earnings per share change (TTM)
-14.71%
3-year earnings per share growth (CAGR)
4.75%
What the Analysts think about DYN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
DYN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DYN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DYN News
AllArticlesVideos
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
GlobeNewsWire·5 days ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·5 days ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Dyne Therapeutics stock?
Dyne Therapeutics (DYN) has a market cap of $924M as of April 20, 2025.
What is the P/E ratio for Dyne Therapeutics stock?
The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of April 20, 2025.
Does Dyne Therapeutics stock pay dividends?
No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Dyne Therapeutics dividend payment date?
Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.
What is the beta indicator for Dyne Therapeutics?
Dyne Therapeutics (DYN) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.